Showing 4,041 - 4,060 results of 4,156 for search '"York"', query time: 0.06s Refine Results
  1. 4041

    Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherap... by Weiming Liang, Weiming Liang, Zhijing Wang, Zhilong Huang, Yanping Huang, Chunyan Li, Yiwen Liang, Miaoyan Huang, Duo Zhang, Chenchen Li

    Published 2025-02-01
    “…Specifically, the combination of Enfortumab vedotin (EV) and pembrolizumab (Pembro) showed more effectiveness in treating patients compared to trials using the current standard treatment, suggesting that it could be a promising alternative treatment option.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42024510152.…”
    Get full text
    Article
  2. 4042
  3. 4043

    Outcomes of patients after successful left ventricular assist device explantation: a EUROMACS study by Christiaan F.J. Antonides, Felix Schoenrath, Theo M.M.H. deBy, Rahatullah Muslem, Kevin Veen, Yunus C. Yalcin, Ivan Netuka, Jan Gummert, Evgenij V. Potapov, Bart Meyns, Mustafa Özbaran, David Schibilsky, Kadir Caliskan, the EUROMACS investigators

    Published 2020-06-01
    “…The median follow‐up after explantation was 26 months (range 0.3–73 months), and 82% of the patients were in New York Heart Association Class I or II. Beta‐blockers were prescribed to 85%, angiotensin‐converting enzyme inhibitors to 71%, and loop diuretics to 50% of the patients, respectively. …”
    Get full text
    Article
  4. 4044

    Safety and efficacy of catheter ablation in atrial fibrillation patients with heart failure with preserved ejection fraction by Songbing Long, Yuanjun Sun, ShiYu Dai, Xianjie Xiao, Zhongzhen Wang, Wei Sun, Lianjun Gao, Yunlong Xia, Xiaomeng Yin

    Published 2025-01-01
    “…Significant improvements in heart function were observed in the AFPHF-CA group compared to the AFPHF-Med group, including reductions in left ventricular end-diastolic diameter (P < 0.001), New York Heart Association classification (P < 0.001), left ventricular mass index (P < 0.001), and left atrial volume index (P < 0.001). …”
    Get full text
    Article
  5. 4045

    The dose–effect relationship between acupuncture and its effect on primary insomnia: a systematic review and meta-analysis by Xiaoni Zhang, Xiaoni Zhang, Yue Wang, Chengyong Liu, Shan Qin, Liyu Lin, Liyu Lin, Can Dong, Wenzhong Wu, Wenzhong Wu, Zhaoming Chen

    Published 2025-02-01
    “…Collectively, the data suggest that at least three sessions per week for 3–4 weeks and a total of at least 12 acupuncture sessions would be the optimal clinical response.Systematic review registrationhttps://www.crd.york.ac.uk/, identifier CRD42024560078.…”
    Get full text
    Article
  6. 4046
  7. 4047
  8. 4048
  9. 4049

    Epidemiological aspects of nephrolithiasis and chronic diseases of the cardiovascular system combination by R. V. Royuk, S. K. Yarovoy, N. A. Guseva, Sh. L. Voskanyan, V. V. Royuk, D. B. Rodin

    Published 2020-03-01
    “…Stages of congestive heart failure were defined according to c NYHA (New York Heart Association) classification. Functional class of stable angina was defined according to Canadian Cardiovascular Society classification (1970,1976). …”
    Get full text
    Article
  10. 4050

    Comprehensive symptom assessment using Integrated Palliative care Outcome Scale in hospitalized heart failure patients by Yasuhiro Hamatani, Moritake Iguchi, Yurika Ikeyama, Atsuko Kunugida, Megumi Ogawa, Natsushige Yasuda, Kana Fujimoto, Hidenori Ichihara, Misaki Sakai, Tae Kinoshita, Yasuyo Nakashima, Masaharu Akao

    Published 2022-06-01
    “…Of 294 patients (mean age: 77.5 ± 12.0 years, male: 168 patients, New York Heart Association class IV: 96 patients, mean left ventricular ejection fraction [LVEF]: 44%, and median N‐terminal pro B‐type natriuretic peptide [NT‐proBNP] level: 4418 ng/L), the median (IQR) total IPOS score on admission was 19 (12, 27) and they were widely distributed (minimum: 0 – maximum: 52). …”
    Get full text
    Article
  11. 4051
  12. 4052
  13. 4053

    Different exercise interventions on quality of sleep in breast cancer survivors—a network meta-analysis of randomized controlled trials by Qi Song, Qi Song, You-kang Zhu, You-kang Zhu, Hai Liu, Hai Liu, Xiao Liu, Xiao Liu, Zhang-dong Jiang, Yu-jia Wang, Yu-jia Wang, Li-yun Xue, Li-yun Xue, Shao-ying Yang, Shao-ying Yang, Xi-fang Liu

    Published 2025-02-01
    “…This finding presents a novel perspective on exercise interventions for breast cancer survivors experiencing sleep disorders.Systematic review registrationPROSPERO https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=442892, identifier CRD42023442892.…”
    Get full text
    Article
  14. 4054
  15. 4055

    Incidence of hyperkalemia RAASi and SGLT-2i treatment in individuals with diabetic kidney disease: a systematic review and network meta-analysis by Yahui Yuan, Yahui Yuan, Yahui Yuan, Chun Chen, Yuping Lin, Yehao Luo, Yehao Luo, Yehao Luo, Zhaojun Yang, Zhaojun Yang, Zhaojun Yang, Jingyi Guo, Jingyi Guo, Jingyi Guo, Qiaoyun Liu, Qiaoyun Liu, Qiaoyun Liu, Lu Sun, Guanjie Fan, Guanjie Fan, Guanjie Fan

    Published 2025-01-01
    “…ACEI/ARB + SGLT-2i mitigated serum potassium level.ConclusionSGLT-2i was effective in reducing the incidence of hyperkalemia incidence, whereas a combination of ACEI/ARB and MRA might elevate the incidence of hyperkalemia in individuals with DKD.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/#recordDetails, identifier CRD42024552810.…”
    Get full text
    Article
  16. 4056
  17. 4057
  18. 4058

    Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review... by Konstantinos Lallas, Eftychia Chatziioannou, Derya Durak, Georg Frey, Lina Maria Serna-Higuita, Marie-Lena Rasch, Athanassios Kyrgidis, Eleni Timotheadou, Zoe Apalla, Ulrike Leiter, Lukas Flatz, Lukas Flatz, Aimilios Lallas, Teresa Amaral, Teresa Amaral

    Published 2025-01-01
    “…Outcomes to rechallenge with ICIs may differ depending on the reason for discontinuation, but remains a considerable option.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42024547792.…”
    Get full text
    Article
  19. 4059

    Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 express... by Fei Yang, Min Dan, Jindan Shi, Ling Fan, Haoluo Zhang, Tiantian Jian, Kelu Lei, Yue Wang, Juan Xin, Zhigang Yu, Wei Chen

    Published 2025-01-01
    “…For patients with PD-L1 expression ≥ 10%, Tislelizumab is expected to offer the greatest efficacy, while Camrelizumab appears to be the most effective for those with PD-L1 &lt; 10%.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024540581.…”
    Get full text
    Article
  20. 4060